Carlos L. Arteaga - Concepedia

Author

Carlos L. Arteaga

Also Known As

Arteaga, C., Arteaga, Carlos L., C ARTEAGA, C Arteaga, C L Arteaga, C. Arteaga, C. L. Arteaga, C.A. Muller Arteaga, C.L. Arteaga, Cao, Z. Alexander

1.3K

Publications

54.8K

Citations

122

H-Index

179

Concepts

All Affiliations

Vanderbilt University Breast Cancer Research Foundation Dana-Farber Cancer Institute The University of Texas Southwestern Medical Center The University of Texas MD Anderson Cancer Center

About

Carlos L. Arteaga is an author at Vanderbilt University specializing in medicine, cell biology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	74	157	21K
2	Health Sciences	17	23	3.3K
3	Engineering	9	9	539
4	Natural Sciences	8	8	1.5K
5	Public Health	1	1	96

Carlos L. Arteaga

322

Publications

43.8K

Citations

111

H-Index

Page 1

	Year	Citations
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer Gabriel N. Hortobágyi, Salomon M. Stemmer, Howard A. Burris, New England Journal of Medicine	2016	1.9K
Transforming Growth Factor-β1 Mediates Epithelial to Mesenchymal Transdifferentiation through a RhoA-dependent Mechanism Neil A. Bhowmick, Mayshan Ghiassi, Andrei V. Bakin, Molecular Biology of the Cell	2001	989
Phosphatidylinositol 3-Kinase Function Is Required for Transforming Growth Factor β-mediated Epithelial to Mesenchymal Transition and Cell Migration Andrei V. Bakin, Anne K. Tomlinson, Neil A. Bhowmick, Journal of Biological Chemistry	2000	980
Measurement of muscle mass in humans: validity of the 24-hour urinary creatinine method Carlos L. Arteaga, C McManus, Janet E. Smith, American Journal of Clinical Nutrition UrologyBody CompositionMuscle FunctionSkeletal MusclePhysiology	1983	860
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer Gabriel N. Hortobágyi, Salomon M. Stemmer, H. A. Burris, Annals of Oncology	2018	839
PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization Incheol Shin, F. Michael Yakes, Federico Rojo, Nature Medicine Signal TransductionSignaling PathwayCell DivisionCell RegulationNatural Sciences	2002	784
HER kinase inhibition in patients with HER2- and HER3-mutant cancers David M. Hyman, Sarina A. Piha‐Paul, Helen Won, Nature Tumor BiologyOncologyMedicineReceptor Tyrosine KinasePathology	2018	752
Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor–Positive Breast Cancer Rinath Jeselsohn, Roman Yelensky, Gilles Buchwalter, Clinical Cancer Research	2014	633
MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation Kyung‐min Lee, Jennifer M. Giltnane, Justin M. Balko, Cell Metabolism Tumor BiologyBreast OncologyMitochondrial FunctionMedicineMitochondrial Oxidative Phosphorylation	2017	625
Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. F. Michael Yakes, Wichai Chinratanalab, Christoph A. Ritter, PubMed Cyclin D1ImmunologyHer2 Gene AmplificationImmunologic MechanismImmunotherapy	2002	617

Page 1